Skip to main content

2025 IDWeek Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session Icons

Live Streamed

On Demand

65 Views

H4. HIV: Treatment

Poster Session: HIV: Treatment

(P-369) Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) after ISL Dose Reduction from 0.75 mg: Week 48 Results from an Open-Label Phase 3 Study

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Virtual

Presenting Author(s)

Rosie Mngqibisa, MD (she/her/hers)

Director
Enhancing Care Foundation
Durban, KwaZulu-Natal, South Africa

Co-Author(s)

SK

Sheetal Kassim, MD

Desmond Tutu Health Foundation
Cape Town, Western Cape, South Africa
CM

Cheryl McDonald, MD

Infectious Disease Specialist
Tarrant County Infectious Disease Associate
Fort Worth, TX, United States
MB

Mark Bloch, MBBS, MMed

Holdsworth House
Syndey, New South Wales, Australia
EC

Eugenie Colin-Benoit, MD

Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern
Bern, Bern, Switzerland
CB

Christopher Bettacchi, MD

Infectious Diseases Physician
North Texas Infectious Disease Consultants
Dallas, Texas, United States
MJ

Margaret Johnson, MD

Royal Free London NHS Foundation Trust
London, England, United Kingdom
HG

Hiroyuki Gatanaga, MD, PhD

National Center for Global Health and Medicine
Shinjuku-ku, Tokyo, Japan
EK

Euna Kim, BA

Merck & Co., Inc.
Rahway, New Jersey, United States
UN

Uche Nwoke, MS

Merck & Co., Inc.
Rahway, New Jersey, United States
MF

Michelle C. Fox, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
LS

Luisa M. Stamm, MD, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
ML

Mengchun Li, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
WG

Wayne Greaves, MD

Executive Director
Merck Research Labs
Edison, NJ, United States